RÉSUMÉ
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease and managed in much the same way. The advent of novel CD20 monoclonal antibodies led to the development of effective chemoimmunotherapy regimens. More recently, small molecule inhibitors targeting kinases involved in a number of critical signaling pathways and a small molecule inhibitor of the BCL-2 family of proteins have demonstrated activity for the treatment of patients with CLL/SLL. These NCCN Guidelines Insights highlight important updates to the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for CLL/SLL for the treatment of patients with newly diagnosed or relapsed/refractory CLL/SLL.
Sujet(s)
Leucémie chronique lymphocytaire à cellules B/diagnostic , Leucémie chronique lymphocytaire à cellules B/thérapie , Protocoles de polychimiothérapie antinéoplasique/effets indésirables , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Comorbidité , Résistance aux médicaments antinéoplasiques , Humains , Leucémie chronique lymphocytaire à cellules B/étiologie , Leucémie chronique lymphocytaire à cellules B/mortalité , Thérapie moléculaire ciblée , Stadification tumorale , Récidive , Reprise du traitement , Résultat thérapeutiqueRÉSUMÉ
Peripheral T-cell lymphomas (PTCLs) represent a relatively uncommon heterogeneous group of non-Hodgkin's lymphomas (NHLs) with an aggressive clinical course and poor prognosis. Anthracycline-based multiagent chemotherapy with or without radiation therapy followed by first-line consolidation with high-dose therapy followed by autologous stem cell rescue (HDT/ASCR) is the standard approach to most of the patients with newly diagnosed PTCL. Relapsed or refractory disease is managed with second-line systemic therapy followed by HDT/ASCR or allogeneic stem cell transplant, based on the patient's eligibility for transplant. In recent years, several newer agents have shown significant activity in patients with relapsed or refractory disease across all 4 subtypes of PTCL. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for NHL, specific to the management of patients with relapsed or refractory PTCL.
Sujet(s)
Lymphome T périphérique/thérapie , Humains , Lymphome T périphérique/anatomopathologie , Guides de bonnes pratiques cliniques comme sujet , Taux de survieRÉSUMÉ
Diffuse large B-cell lymphomas (DLBCL) are now considered a heterogeneous group of distinct molecular subtypes (germinal center B-cell DLBCL, activated B-cell DLBCL, and primary mediastinal large B-cell lymphoma (PMBL) with varied natural history and response to therapy. In addition, a subset of patients with DLBCL have concurrent MYC and/or BCL2 gene rearrangements (double-hit lymphomas; DHL) and others have a dual expression of both MYC and BCL2 proteins (double-expressing DLBCL; DEL). The standard of care for the treatment of patients with PMBL, DHL, or DEL has not been established. Adequate immunophenotyping and molecular testing (in selected circumstances) are necessary for the accurate diagnosis of different subtypes of DLBCL. The NCCN Guidelines included in this issue, part of the NCCN Guidelines for non-Hodgkin's lymphomas, address the diagnosis and management of DLBCL and its subtypes.
Sujet(s)
Lymphome B diffus à grandes cellules/traitement médicamenteux , Lymphome B diffus à grandes cellules/génétique , Réarrangement des gènes/génétique , Humains , Immunophénotypage/méthodes , Protéines proto-oncogènes c-bcl-2/génétique , Protéines proto-oncogènes c-myc/génétiqueRÉSUMÉ
Chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) are different manifestations of the same disease, which are managed in the same way. The advent of novel monoclonal antibodies (ofatumumab and obinutuzumab) led to the development of effective chemoimmunotherapy regimens. The recently approved small molecule kinase inhibitors (ibrutinib and idelalisib) are effective treatment options for CLL in elderly patients with decreased tolerance for aggressive regimens and in patients with poor prognostic features who do not benefit from conventional chemoimmunotherapy regimens. This portion of the NCCN Guidelines for Non-Hodgkin's Lymphomas describes the recent specific to the incorporation of recently approved targeted therapies for the management of patients with newly diagnosed and relapsed or refractory CLL/SLL.
Sujet(s)
Leucémie chronique lymphocytaire à cellules B/diagnostic , Leucémie chronique lymphocytaire à cellules B/thérapie , Algorithmes , Comorbidité , Prise en charge de la maladie , Humains , Leucémie chronique lymphocytaire à cellules B/épidémiologie , Leucémie chronique lymphocytaire à cellules B/étiologie , Stadification tumorale , PronosticRÉSUMÉ
Non-Hodgkin's lymphomas (NHL) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Mantle cell lymphoma (MCL) accounts for approximately 6% of all newly diagnosed NHL cases. Radiation therapy with or without systemic therapy is a reasonable approach for the few patients who present with early-stage disease. Rituximab-based chemoimmunotherapy followed by high-dose therapy and autologous stem cell rescue (HDT/ASCR) is recommended for patients presenting with advanced-stage disease. Induction therapy followed by rituximab maintenance may provide extended disease control for those who are not candidates for HDT/ASCR. Ibrutinib, a Bruton tyrosine kinase inhibitor, was recently approved for the treatment of relapsed or refractory disease. This manuscript discusses the recommendations outlined in the NCCN Guidelines for NHL regarding the diagnosis and management of patients with MCL.
Sujet(s)
Lymphome malin non hodgkinien/diagnostic , Lymphome malin non hodgkinien/thérapie , Humains , Stadification tumorale , RécidiveRÉSUMÉ
Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.
Sujet(s)
Anticorps monoclonaux d'origine murine/administration et posologie , Lymphome folliculaire/traitement médicamenteux , Lymphome malin non hodgkinien/traitement médicamenteux , Récidive tumorale locale/traitement médicamenteux , Protocoles de polychimiothérapie antinéoplasique/administration et posologie , Survie sans rechute , Humains , Lymphome folliculaire/diagnostic , Lymphome folliculaire/anatomopathologie , Lymphome malin non hodgkinien/diagnostic , Lymphome malin non hodgkinien/anatomopathologie , Récidive tumorale locale/diagnostic , Récidive tumorale locale/anatomopathologie , Radioimmunothérapie , RituximabRÉSUMÉ
These NCCN Guidelines Insights summarize several key updates to the NCCN Guidelines for Non-Hodgkin's Lymphomas (NHL) and provide a discussion of the clinical evidence that support the updates. The updates discussed in this article feature recommendations for additional treatment options in patients with chronic lymphocytic leukemia and guidance surrounding the management of hepatitis virus reactivation/infections in high-risk patients with NHL undergoing antitumor therapy.
Sujet(s)
Lymphome malin non hodgkinien/thérapie , Antinéoplasiques/effets indésirables , Antinéoplasiques/usage thérapeutique , Hépatite B/sang , Hépatite B/induit chimiquement , Hépatite B/immunologie , Anticorps de l'hépatite B/sang , Antigènes de surface du virus de l'hépatite B/sang , Virus de l'hépatite B/effets des médicaments et des substances chimiques , Virus de l'hépatite B/immunologie , Virus de l'hépatite B/physiologie , Hépatite C/complications , Hépatite C/traitement médicamenteux , Humains , Lénalidomide , Leucémie chronique lymphocytaire à cellules B/sang , Leucémie chronique lymphocytaire à cellules B/thérapie , Leucémie chronique lymphocytaire à cellules B/virologie , Lymphome malin non hodgkinien/sang , Lymphome malin non hodgkinien/virologie , Thalidomide/effets indésirables , Thalidomide/analogues et dérivés , Thalidomide/usage thérapeutique , Activation virale/effets des médicaments et des substances chimiquesRÉSUMÉ
These NCCN Guidelines Insights summarize several key updates to the 2012 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas (NHL) and describe the clinical evidence supporting the updates. The featured updates include changes to the recommendations for treatment options in patients with chronic lymphocytic leukemia (including in elderly or frail patients and patients with poor-risk cytogenetics), guidance surrounding surveillance imaging for follow-up of patients with NHL, and the addition of first-line consolidation options for patients with mantle cell lymphoma.